Radiation | Jotup

Regulatory Clearance for Leo Cancer Care's Upright Technology for Radiation Therapy

Retrieved on:

четверг, мая 9, 2024

FDA, PMN, Cancer, Radiation, Food, Research, Patient, Movement, Pharmaceutical industry

MIDDLETON, Wis., May 9, 2024 /PRNewswire/ -- Leo Cancer Care is delighted to announce that it has gained regulatory clearance for its revolutionary upright patient positioning system for delivering radiotherapy treatment to patients. This 510(K) clearance means that the Eve System can now be used to offer 'a more human' method of treating cancer patients.

Key Points:

510k regulatory clearance for Leo Cancer Care's unique patient positioning system, Eve®, paves the way for a new approach to patient treatment
MIDDLETON, Wis., May 9, 2024 /PRNewswire/ -- Leo Cancer Care is delighted to announce that it has gained regulatory clearance for its revolutionary upright patient positioning system for delivering radiotherapy treatment to patients.
The patient positioning system enables cancer patients to receive radiation treatment seated in an upright position.
The FDA regulatory clearance for Leo Cancer Care's upright technology is a truly significant step in the company's evolution, and also in the way radiation therapy can now be delivered to patients.
Towe said that with one device cleared, Leo Cancer Care has a comprehensive development pipeline to deliver further solutions within the upright technology paradigm.

Regulatory Clearance for Leo Cancer Care's Upright Technology for Radiation Therapy

Retrieved on:

четверг, мая 9, 2024

FDA, PMN, Cancer, Radiation, Food, Research, Patient, Movement, Pharmaceutical industry

MIDDLETON, Wis., May 9, 2024 /PRNewswire/ -- Leo Cancer Care is delighted to announce that it has gained regulatory clearance for its revolutionary upright patient positioning system for delivering radiotherapy treatment to patients. This 510(K) clearance means that the Eve System can now be used to offer 'a more human' method of treating cancer patients.

Key Points:

510k regulatory clearance for Leo Cancer Care's unique patient positioning system, Eve®, paves the way for a new approach to patient treatment
MIDDLETON, Wis., May 9, 2024 /PRNewswire/ -- Leo Cancer Care is delighted to announce that it has gained regulatory clearance for its revolutionary upright patient positioning system for delivering radiotherapy treatment to patients.
The patient positioning system enables cancer patients to receive radiation treatment seated in an upright position.
The FDA regulatory clearance for Leo Cancer Care's upright technology is a truly significant step in the company's evolution, and also in the way radiation therapy can now be delivered to patients.
Towe said that with one device cleared, Leo Cancer Care has a comprehensive development pipeline to deliver further solutions within the upright technology paradigm.

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

Retrieved on:

четверг, мая 9, 2024

LONDON and NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points:

MeiraGTx anticipates receiving an additional $15 million in near-term milestone payments later in 2024.
As of March 31, 2024, MeiraGTx had cash and cash equivalents of approximately $119.2 million and in April 2024, the Company collected $19.7 million in receivables which were due in the first quarter of 2024, effectively increasing the cash balance to $138.9 million.
The increase of $0.6 million was due to higher interest rates and cash balances during 2024.
Interest expense was $3.3 million for the three months ended March 31, 2024, compared to $3.1 million for the three months ended March 31, 2023.

Largest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Healthcare’s SRT-100™ to Provide Gentler Radiotherapy to Treat Tumors in Dogs and Cats

Retrieved on:

четверг, мая 9, 2024

Knowledge, Sale, Fort Collins, Colorado, Radiation, Animal, Colorado State University, Beit Berl College, Turtle, SRT, Cat, Veterinary medicine, Patient, Emergency, Neoplasm, Dog, Bird, CSU, Horse, Medical imaging

BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of an SRT-100 system to Chavat Da’at, the Veterinary Specialist Referral Center Knowledge Farm at Beit Verl College in Tel Aviv, to provide a gentler radiotherapy option to treat tumors in dogs and cats. This is the first commercial sale of the SRT-100 for veterinary use outside the U.S.

Key Points:

Soon thereafter, an Emergency and Critical Care Center was established, which operates 24 hours a day.
Knowledge Farm is the largest private Veterinary Specialty Referral Center in Israel with more than 20 board-certified specialists and emergency physicians, and more than 30 qualified veterinary technicians and support staff.
“Whether for treating small animals like cats, dogs, turtles and birds, or large ones like horses, our technology is a valuable addition to leading veterinary practices worldwide.
These leaders are exploring and expanding the veterinary indications for radiotherapy, while making treatments increasingly available and affordable to many more pet owners,” he added.

GSI Technology Reiterates Key Takeaways From Q4 FY2024 Earnings Call and Provides Q&A

Retrieved on:

четверг, мая 9, 2024

SUNNYVALE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- GSI Technology, Inc. (Nasdaq: GSIT), the inventor of the Associative Processing Unit (APU), a paradigm shift in AI and HPC processing providing true compute-in-memory technology, today reiterated the key highlights from its recent earnings call for the fourth quarter of fiscal year 2024 held on Thursday, May 2, 2024.

Key Points:

This is the first Rad Hard shipment for a non-U.S.-based mission, giving GSI exposure within the ESA community.
Announced initiating a broad strategic review to maximize stockholder value and retained Needham & Company, LLC as the strategic and financial advisor.
GSI’s software team is actively writing libraries to develop new applications on the edge or near the edge for Gemini-II.
“Engaging Needham & Company underscores our proactive approach to fortifying our market position and financial health and maximizing stockholder value,” said Lee-Lean Shu, CEO of GSI Technology.

DIII-D National Fusion Facility Completes Upgrade

Retrieved on:

среда, мая 8, 2024

Science, Tungsten, DIII, Radiation, DOE, Sir, Element, Power, Physics, DIII-D, Metal, PCS, CER, Office of Science, Field line, Heat, Radial, Microwave, Plasma, Research, SVR, Shoot, ITER, Pressure, Electronics, FPP, Gas, Temperature, Behavior

San Diego, CA, May 08, 2024 (GLOBE NEWSWIRE) -- The DIII-D National Fusion Facility has completed a series of important enhancements, providing researchers with several first-of-a-kind tools for controlling and understanding the function of fusion plasmas.

Key Points:

San Diego, CA, May 08, 2024 (GLOBE NEWSWIRE) -- The DIII-D National Fusion Facility has completed a series of important enhancements, providing researchers with several first-of-a-kind tools for controlling and understanding the function of fusion plasmas.
The facility has been offline since July 2023 as a multi-institutional team of engineers and technicians worked to install new capabilities.
Together, the new technologies installed during the eight-month upgrade will play a key role in developing the scientific basis for fusion as a reliable and nearly limitless energy source.
When experiments restart in May, researchers will use these tools to optimize the performance of fusion plasmas and help bring practical fusion energy closer to reality.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HireRight, Checkpoint, Ocugen, and Sonder Innovations and Encourages Investors to Contact the Firm

Retrieved on:

среда, мая 8, 2024

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points:

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
That same day, pursuant to the Offering Documents, HireRight’s common stock began publicly trading on the New York Stock Exchange (“NYSE”) under the ticker symbol HRT.
cites findings that arose during a multi-sponsor inspection of Checkpoint's third-party [CMO] as approvability issues to address in a resubmission."
For more information on the Sonder class action go to: https://bespc.com/cases/SOND

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Checkpoint

Retrieved on:

среда, мая 8, 2024

FDA, Radiation, CMO, LLP, News, Advertising, Patient, Court, CKPT, BLA, CRL, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points:

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Checkpoint’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Radiation-Tolerant DC-DC 50-Watt Power Converters Provide High-Reliability Solution for New Space Applications

Retrieved on:

вторник, мая 7, 2024

QML, Radiation, Microchip Technology, LEO, Internet of things, Integrated circuit, MCHP, DC-DC, Family, Field-programmable gate array, EMI, TID, RT, Linear energy transfer, COTS

There is an increased demand for standard space grade solutions that are reliable, cost effective and configurable.

Key Points:

There is an increased demand for standard space grade solutions that are reliable, cost effective and configurable.
The off-the-shelf LE50-28 family of power converters are designed to meet MIL-STD-461.
This series provides flexibility to parallel up to four power converters to reach 200-Watts.
Designed to serve 28V bus systems, the LE50-28 isolated DC-DC power converters can be integrated with Microchip’s PolarFire® FPGAs, microcontrollers and LX7720-RT motor control sensor for a complete electrical system solution.

CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on:

понедельник, мая 6, 2024

FDA, Radiation, CMO, News, Complaint, Patient, Court, CKPT, BLA, CRL, Person

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.

Key Points:

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies.
or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
If you suffered a loss in Checkpoint you have until June 4, 2024, to request that the Court appoint you as lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.